NO20023913L - Deskripsjons TNF-alfa inhibitorer - Google Patents

Deskripsjons TNF-alfa inhibitorer

Info

Publication number
NO20023913L
NO20023913L NO20023913A NO20023913A NO20023913L NO 20023913 L NO20023913 L NO 20023913L NO 20023913 A NO20023913 A NO 20023913A NO 20023913 A NO20023913 A NO 20023913A NO 20023913 L NO20023913 L NO 20023913L
Authority
NO
Norway
Prior art keywords
tnf
descriptive
alpha inhibitors
inhibitors
alpha
Prior art date
Application number
NO20023913A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023913D0 (no
Inventor
Kazuaki Ikeya
Takahito Kitayoshi
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20023913D0 publication Critical patent/NO20023913D0/no
Publication of NO20023913L publication Critical patent/NO20023913L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20023913A 2000-02-18 2002-08-16 Deskripsjons TNF-alfa inhibitorer NO20023913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000046828 2000-02-18
PCT/JP2001/001069 WO2001060362A1 (en) 2000-02-18 2001-02-15 TNF-α INHIBITORS

Publications (2)

Publication Number Publication Date
NO20023913D0 NO20023913D0 (no) 2002-08-16
NO20023913L true NO20023913L (no) 2002-09-10

Family

ID=18569174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023913A NO20023913L (no) 2000-02-18 2002-08-16 Deskripsjons TNF-alfa inhibitorer

Country Status (10)

Country Link
US (1) US6833381B2 (ja)
EP (1) EP1262180A4 (ja)
KR (1) KR20030016229A (ja)
CN (1) CN1404390A (ja)
AU (2) AU3408801A (ja)
CA (1) CA2400124C (ja)
HU (1) HUP0301057A3 (ja)
NO (1) NO20023913L (ja)
PL (1) PL356422A1 (ja)
WO (1) WO2001060362A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100224601B1 (ko) * 1997-05-13 1999-10-15 윤종용 복합기의 자동 급지장치
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
CA2436361C (en) * 2001-01-29 2010-11-02 Takeda Chemical Industries, Ltd. Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1390518B1 (de) * 2001-04-23 2004-10-06 Amaxa GmbH Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben
WO2003041739A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제
US20050201989A1 (en) * 2004-02-19 2005-09-15 St. Camillus Medical, Inc. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha
BRPI0510110A (pt) * 2004-04-23 2007-09-25 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
CA2575177A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP1891952B1 (en) * 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
AU2008235790B2 (en) * 2007-03-28 2013-06-06 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8236843B2 (en) 2008-09-02 2012-08-07 Elder Pharmaceuticals Ltd. Anti inflammatory compounds
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
GB201620948D0 (en) * 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
CN118105392A (zh) * 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
AU1423795A (en) * 1994-02-08 1995-08-29 Novartis Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
IL122246A (en) * 1995-06-07 2004-06-01 Searle & Co Combination of spironolactone and angiotensin II antagonist for the treatment of heart failure
WO1997002032A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
KR19990087076A (ko) 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
PT966282E (pt) * 1997-01-10 2003-10-31 Merck & Co Inc Uso de antagonistas da angiotensina ii para tratar a insuficiencia cardiaca sintomatica
AU747110B2 (en) * 1998-02-25 2002-05-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
IL137979A0 (en) * 1998-03-04 2001-10-31 Takeda Chemical Industries Ltd Production, release preparation for aii antagonist-sustained and use thereof
JP2000159671A (ja) * 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
US6833381B2 (en) 2004-12-21
WO2001060362A1 (en) 2001-08-23
US20030055039A1 (en) 2003-03-20
EP1262180A4 (en) 2005-06-01
NO20023913D0 (no) 2002-08-16
KR20030016229A (ko) 2003-02-26
AU2001234088B2 (en) 2005-12-01
AU3408801A (en) 2001-08-27
CN1404390A (zh) 2003-03-19
EP1262180A1 (en) 2002-12-04
PL356422A1 (en) 2004-06-28
CA2400124A1 (en) 2001-08-23
HUP0301057A2 (hu) 2003-12-29
HUP0301057A3 (en) 2004-01-28
CA2400124C (en) 2010-12-14

Similar Documents

Publication Publication Date Title
NO20023913L (no) Deskripsjons TNF-alfa inhibitorer
DE50105915D1 (de) Schutzhülle
CY2012007I1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
ATE524441T1 (de) Vla-4-inhibitoren
DE60116273D1 (de) Tabakverarbeitung
NO20001333D0 (no) Ereksjonshjelpemiddel
DE60112603D1 (de) Perkutane aortenklappe
DE60110402D1 (de) Strukturverbaupanele
ATE290000T1 (de) Muscarinagonisten
DE60142394D1 (de) Biozensor
DE60119792D1 (de) Druckspeicher
DE60105471D1 (de) Videoskop
DE60126562D1 (de) Durchfflussregelventil
DE60135663D1 (de) Ngskopplung
DE60119505D1 (de) Kraftstoffschlauch
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016231D0 (no) Luftspaltningsinnretning
DE60025150D1 (de) Brennkammerverwirbelungsanordnung
NO20025786D0 (no) Protaseinhibitorer
NO20025005L (no) Proteaseinhibitorer
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
NO20032328L (no) Proteaseinhibitorer
ATE284887T1 (de) Thienopyrrolidinone
NO20013985L (no) Orto-fenylfenolatkonsentrater
DE60110550D1 (de) Deichsel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application